Dr Reddys Laboratories, an integrated global pharmaceutical company, will announce its first quarter financial results today, Jul. 30, 2015.

Commenting on the quarterly results, Angel Broking said, ''Dr Reddy (DRL), for its 1QFY2016 results, is expected to post a 13.7% yoy growth in sales on top line to end the period at Rs 40 billion, mainly driven by exports. The EBDITA margins are expected to come in at 23.3% v/s 23.2% in 1QFY2015.

R&D expenditure during the quarter is expected to be 12.9% of sales V/s 11.0% of sales in 1QFY2015. Consequently; the PAT is expected to come in at Rs 6.42 billion V/s Rs 5.50 billion in 1QFY2015, a growth of 16.6% yoy. We maintain our accumulate rating on the stock, on back of valuations.''

Shares of the company gained Rs 44.8, or 1.21%, to trade at Rs 3,758.00. The total volume of shares traded was 4,092 at the BSE (10.12 a.m., Thursday).